Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy
uses high energy x-rays to kill tumor cells. Erlotinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together
with bevacizumab, radiation therapy, and erlotinib may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of bevacizumab and
erlotinib when given together with combination chemotherapy and radiation therapy and to see
how well they work in treating patients with stage III non-small cell lung cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborators:
Eli Lilly and Company Genentech, Inc. National Cancer Institute (NCI)